

Medicare GLP-1 Bridge

Current Program Duration: Jul 2026 – Dec 2027



Table of Contents

- I. Program Overview:
 - a. Patient
 - i. Eligibility
 - ii. Handouts
 - b. Pharmacy
 - i. Products & Performance
 - ii. Prescribing & Prior Authorization Workflow

Patient Eligibility at a Glance

Patients must be 18 or older and meet one of the criteria below at the time GLP-1 therapy was initiated:

BMI ≥ 35

- Severe obesity
- BMI alone meets the requirements
- No additional conditions required

BMI ≥ 30 , *plus one below:*

- Heart failure with preserved ejection fraction
- Uncontrolled hypertension ($>140/90$)
- Chronic kidney disease (stage 3a or higher)

BMI ≥ 27 , *plus one below:*

- Prediabetes
- Previous heart attack
- Previous stroke
- Symptomatic peripheral artery disease

Printable patient handouts:

- Official Medicare Handout: [Medicare GLP-1 Bridge: GLP-1 Drugs for \\$50 a Month](#)
- Additional Patient Info: [GLP-1 Bridge: Overview for Beneficiaries](#)

Covered Medications

All formulations covered



00169-4525-14	Tablets	00002-4178-31
00169-4505-14	00169-4415-31	00002-4503-31
00169-4501-14	00169-4404-31	00002-4794-31
00169-4517-14	00169-4409-31	00002-4803-31
00169-4524-14	00169-4425-31	00002-4839-31
00169-4572-14		00002-4953-31

No single-dose



00002-3566-11
00002-3555-11
00002-3544-11
00002-3533-11
00002-3522-11
00002-3511-11

This list of products/NDCs may be updated by CMS.

Performance

Rate of Reimbursement (RoR)

Part D Brand:
WAC Minus

GLP-1 Bridge:
WAC+Disp. Fee

Humana RoR: (AWP Minus)

Brand: -21.7%
GLP-Bridge: -16.7%

↑ (Highest)
Avg Revenue:
Wegovy

GLP-1 Bridge Profitability

Weighted
Average:

\$31 per Rx
3.5% GPM

↓ (Lowest) Cost:
Zepbound <10mg

↑ Profit \$:
Wegovy

↑ Profit %:
Zepbound

Prescribing & Prior Authorization (PA) Workflow

PRESCRIBER

1. Confirm Plan & Clinical Eligibility

- Confirm patient has standalone prescription drug plan (PDP), or
- Medicare Advantage plan with Rx drug coverage
- Patient must meet clinical requirements

PRESCRIBER

2. Prescribe Eligible Drug, Send to Pharmacy

- 28 or 30-day only
- Note patient's obesity Dx code on Rx (E66 family)
- Indicate: "SEND TO BRIDGE FOR WEIGHT MANAGEMENT"

PHARMACY

3. Submit Claim to Humana

- **BIN: 028918**
- **PCN: MEDDGLP1BR**
- Humana provides resubmit instructions for denied claims
- Eligible claims will be denied and will notify the pharmacy of the PA requirement

PRESCRIBER

4. Submit PA Request to Humana

- Approval or denial mailed to patient, communicated to prescriber via ePA or fax within 72 hours

A denied pharmacy claim **must** be submitted to GLP-1 Bridge BIN (028918) PCN (MEDDGLP1BR) **prior** to prescriber submitting PA request.

- Pharmacy use handouts:
 - [CMS: Information for Pharmacies](#)
 - [Medicare GLP-1 Bridge Prior Authorization Request Form](#)
 - [NCPDP Reject Code Troubleshooting Tool](#)
 - [GLP-1 Bridge Payer Sheet](#)
 - [Cencora: Medicare GLP-1 Bridge Information Sheet](#)
- CMS contact info:
 - Email: glp1demo@cms.hhs.gov
 - Phone: 800.633.4227
- Anticipate that each patient's first fill will require prior authorization
- **After first fill PA is approved, subsequent fills do not require new PA unless patient switches covered GLP-1 drugs**
- A test claim may be billed to the patient's existing Part D plan to confirm coverage, but this is not required
 - Note: The test claim will likely not be covered as Medicare does not cover weight loss only medications.
- Discount or manufacturer savings cards cannot be applied to these claims and costs will not apply to the patient's Part D cap
- Expected reimbursement: The NDC's wholesale acquisition cost (WAC) minus the \$50 copay, plus a dispensing fee:
 - \$3 per retail claim
 - \$5 per LTC claim
- **Zepbound® KwikPen® requires a compatible pen needle (not included); consider offering needles to each patient, as applicable**
 - Pen needles are not covered by Medicare GLP-1 Bridge; do not bill to Medicare GLP-1 Bridge or the patient's Part D plan
 - Pen needle sizes used may differ; Members have access to multiple options with contract pricing in ABC Order

Additional patient considerations:

- How will side effects be monitored?
- How will we protect muscle, strength, and nutrition?
- Bring your medication list if not an existing pharmacy patient

GLP-1 Bridge patient opportunity is significant:

- 13M+ Medicare beneficiaries met the BMI thresholds for obesity/overweight in 2023
 - Not all are potentially eligible for GLP-1 Bridge
- ~7% of all 56M Part A & B enrollees are likely candidates